Karen LeVert, CEOSoutheast TechInventures (STI)Research Triangle Park, NC919-941-6080 x100klevert@setechinv.comwww.southeasttechinventures.com

University Technology Commercialization

February 21, 2008

Southeast TechInventures (STI) is a technology accelerator focused on developing and transitioning promising technologies from university labs to the commercial marketplace

“Discovery consists of seeing what everybody has seen, and thinking what nobody has thought.”

- Dr. Albert Szent-Gyorgi

• Work in partnership with Technology Transfer Office to evaluate technologies for commercialization

• Use SBIR Grants for prototype development funding

• Establish master license agreement to streamline licensing of

intellectual property • Goal: Spin-off Company creation, CEO, Business Plan,

Funding • STI receives an equity ownership stake in Spin-off company

in return for services

STI Process

Innovation is the process of converting new ideas or inventions into new products and services that improve efficiency, effectiveness or quality of life. Is it:

• A significant solution to a significant problem?

• Technology Push vs. Market Pull?

• Compelling Opportunity – Uniqueness, Sustainable Advantage, Market Need, Business Model, Fundability, etc.?

Commercial Opportunity

Assessment

• 12 Spin-off Companies

• Varying stages from prototype development to having raised B round of financing with 20 employees

• Actively involved in commercialization efforts of 5 universities

• Current Technology Focus: Biotechnology (medical devices, drug delivery, no pharma presently), Photonics, Nanotechnologies, Materials

• Very well-connected with several SE Angel Investment groups and VC firms

STI at 4 years old

• Dr. Joseph Izatt – Renown researcher in the field of Optical Coherence Tomography, recipient of multiple university NIH grants

• Partnered with STI and secured 3 Phase I SBIR grants and 2 Phase II SBIR grants

• Proof of concept is great! Incorporated Bioptigen. Eric Buckland (20+ years of commercializing advanced optical technologies) becomes CEO.

• Activities: Patent protection, Market validation, Customer feedback, Market assessment

• Raised A Round in 2005, Raising B Round now

• Company will be cash flow positive this year – 18+ employees

Bioptigen Case Study

Spectral DomainOptical Coherence Tomography

(SDOCT)

Addressing the Ophthalmic Diagnosis Gap

October 2007

Confidential

Apr 19, 20239

Confidential

Ophthalmic Diagnosis GapOphthalmic Diagnosis Gap

• Costs of Eye Disease and Vision Care to US Economy

– $48B in direct and $18B in indirect costs

– 15M people suffer from Glaucoma, Macular Degeneration, and Diabetic Retinopathy

– 1.4M LASIK procedures are performed each year

• Diagnosis Gap

– Diagnosis is too complex and too late

– Macular Degeneration diagnosed post-symptomatic

– Glaucoma detected after damage to retina and nerve head

– Retinopathy often precedes other symptoms of diabetes

– New Diagnostics required to catch and manage disease from earliest stages

Confidential

Apr 19, 202310

Confidential

From OCT to SDOCTFrom OCT to SDOCT

Gen 2 SDOCT highlights specific pathologies

Gen 1 OCT shows vague signature of disease

SDOCT Generates its own Fundus Photograph

Large drusen

PRL thinning

OCT requires separate Fundus photograph

Stratus OCT

SDOCT

Confidential

Apr 19, 202311

Confidential

Products for the Clinic and ResearchProducts for the Clinic and ResearchClinical Ophthalmic Scanner

SDOCT MicroscopeHand Held Probe

Adolescent and adult patients

Pediatrics, immobile patients, and animal models

Ex-Vivo tissue samples, small animal models

Thank You